Cardiovascular effects of nisoldipine in essential hypertension. 1994

A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
Department of Nephrology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

The acute hemodynamic effects of nisoldipine (Bay K552) in patients with essential hypertension were studied using nuclear ventriculography. In a cohort of 16 essential hypertension patients, an oral dose of 15 mg nisoldipine significantly lowered blood pressure within 20 min. The effect lasted at least 3 h. Blood pressure that was 160.5 +/- 20.3/108.0 +/- 10.1 mm Hg initially was reduced to 137.0 +/- 14.9/93.8 +/- 9.4 mm Hg at 3 h (P < 0.001). Cardiac output rose, total peripheral resistance fell and ejection fraction rose significantly. End systolic and end diastolic volumes did not change significantly with this dose of nisoldipine. The acute hemodynamic effects of 15 mg nisoldipine administered orally, measured by repeat nuclear ventriculography, were maintained during therapy for the 8 weeks of observation. Thus, nisoldipine is a powerful antihypertensive agent, significantly decreasing BP as well as total peripheral resistance and increasing cardiac index. This effect was prominent after 3 h and wore off about 12 h after each dose. Five of the patients had an initially high heart rate. To these patients propranolol was added in small doses (20-40 mg/day, mean 25 +/- 26 mg/day). This addition did not change the results when the patients were analyzed separately.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
July 1991, The American journal of cardiology,
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
November 1987, Clinical pharmacology and therapeutics,
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
March 1987, Deutsche medizinische Wochenschrift (1946),
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
January 1986, Acta medica Scandinavica. Supplementum,
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
March 1989, Arzneimittel-Forschung,
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
May 1987, Circulation,
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
January 1982, Hypertension (Dallas, Tex. : 1979),
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
May 1995, Hypertension (Dallas, Tex. : 1979),
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
January 1984, Arzneimittel-Forschung,
A Blau, and D Herzog, and I Herz, and A Battler, and P Schechter, and H E Eliahou
January 1990, Materia medica Polona. Polish journal of medicine and pharmacy,
Copied contents to your clipboard!